UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2013
_______________________
BioLineRx Ltd.
(Translation of Registrant’s name into English)
_______________________
P.O. Box 45158
19 Hartum Street
Jerusalem 91450, Israel
(Address of Principal Executive Offices)
_______________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F þ Form 40-F o
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
Yes o No þ
Item 8.01 Other Events
BioLineRx Ltd. (the “Company”) announced that on March 4, 2013, Yakov Friedman, a director, resigned from the Company’s Board, noting that, because he believes the Company’s stock is significantly undervalued, he disagreed with the Board’s decisions to engage in capital-raising transactions and recommended instead that the Company make the most efficient use of its existing cash.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
BioLineRx Ltd.
|
||
|
|
By:
|
/s/ Philip Serlin
|
||
|
|
|
|
Philip Serlin
|
|
|
|
|
|
Chief Financial and Operating Officer
|
|
Date: March 6, 2013